<DOC>
	<DOC>NCT01454739</DOC>
	<brief_summary>The primary objective of the study is to evaluate the long-term safety of recombinant human Factor VIII Fc fusion protein (rFVIIIFc) in participants with hemophilia A. The secondary objective of the study is to evaluate the efficacy of rFVIIIFc in the prevention and treatment of bleeding episodes in participants with hemophilia A.</brief_summary>
	<brief_title>Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A</brief_title>
	<detailed_description>Participant will follow either a prophylaxis or on-demand regimen. The starting dose in this study will be determined by the clinical profile of the participant in the preceding studies A-LONG - 997HA301 (NCT01181128), pediatric study 8HA02PED (NCT01458106) and 997HA307 (NCT02083965).</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Key Subjects who have completed previous rFVIIIFc studies (NCT01181128, NCT02083965 and NCT01458106) Ability to understand purposes and risks of the study and to provide signed and dated informed consent (or assent, as applicable). Key Confirmed positive hightiter inhibitor (â‰¥5.00 BU/mL). NOTE: Other protocol defined Inclusion/Exclusion criteria may apply</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>rFVIIIFc</keyword>
	<keyword>A-LONG Extension</keyword>
</DOC>